Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member with Impressive CSO, Senior Research Background
- Dan Handley brings wealth of invaluable experience to POAI’s board of directors
- Newest board member has extensive experience with entities closely associated with POAI’s Helomics division
- Predictive Oncology set to benefit from Handley’s broad knowledge, expertise
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, has announced the unanimous appointment of its newest board member (http://nnw.fm/TlGT0). Dr. Dan Handley, MS, PhD, brings a wealth of invaluable experience to POAI’s already impressive board of directors.
“Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors,” POAI CEO Dr. Carl Schwartz stated in a news release. “Dan Handley has a varied and strong background, including interaction with Carnegie Mellon University and Magee-Women’s Research Institute – both leaders in their respective fields and closely associated with our Helomics division. I greatly anticipate working with Dan and benefitting from his knowledge and experience.”
Currently serving as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences, Handley has also served as chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 nonprofit corporation. During his time at the Genome Research Institute, Handley held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University.
Other roles Handley has filled include chief scientific officer for Advanced Healthcare Technology Solutions Inc.; senior researcher at Procter & Gamble; senior administrator, researcher and laboratory manager at the David Geffen UCLA School of Medicine; and a founding biotechnology inventor for the National Genetics Institute.
Handley holds a BA in biophysics from Johns Hopkins University, an MS in logic and computation from Carnegie Mellon University and a PhD in human genetics from the University of Pittsburgh. In addition, he completed his postdoctoral training at Magee-Women’s Research Institute where his research focused on advanced genomic technologies applied to fetal and maternal health. A decorated veteran, Handley served as a nuclear propulsion instructor and a submarine nuclear reactor operator during his time with the U.S. Navy.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Dan Handley brings wealth of invaluable experience to POAI’s board of directors
- Newest board member has extensive experience with entities closely associated with POAI’s Helomics division
- Predictive Oncology set to benefit from Handley’s broad knowledge, expertise
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, has announced the unanimous appointment of its newest board member (http://nnw.fm/TlGT0). Dr. Dan Handley, MS, PhD, brings a wealth of invaluable experience to POAI’s already impressive board of directors.
“Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors,” POAI CEO Dr. Carl Schwartz stated in a news release. “Dan Handley has a varied and strong background, including interaction with Carnegie Mellon University and Magee-Women’s Research Institute – both leaders in their respective fields and closely associated with our Helomics division. I greatly anticipate working with Dan and benefitting from his knowledge and experience.”
Currently serving as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences, Handley has also served as chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 nonprofit corporation. During his time at the Genome Research Institute, Handley held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University.
Other roles Handley has filled include chief scientific officer for Advanced Healthcare Technology Solutions Inc.; senior researcher at Procter & Gamble; senior administrator, researcher and laboratory manager at the David Geffen UCLA School of Medicine; and a founding biotechnology inventor for the National Genetics Institute.
Handley holds a BA in biophysics from Johns Hopkins University, an MS in logic and computation from Carnegie Mellon University and a PhD in human genetics from the University of Pittsburgh. In addition, he completed his postdoctoral training at Magee-Women’s Research Institute where his research focused on advanced genomic technologies applied to fetal and maternal health. A decorated veteran, Handley served as a nuclear propulsion instructor and a submarine nuclear reactor operator during his time with the U.S. Navy.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
